Reference
- Pope M. Mucosal dendritic cells and immunodeficiency viruses. J. Infect. Dis. 179\(Suppl. 3), S427 (1999).
- Geijtenbeek TBH, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T-cell. Cell 100, 587–597 (2000).
- Turville S, Wilkinson J, Cameron P, Dable J, Cunningham AL. The role of dendritic cell c-type lectin receptors in HIV pathogenesis. J. Leukoc. Biol. 74, 710–718 (2003).
- McDonald D, Wu L, Bohks SM, et al. Recruitment of HIV and its receptors to dendritic cell-T-cell junctions. Science 300, 1295–1297 (2003).
- •State-of-the-art review of the revised role of dendritic cells and the formation of infectious synapses.
- Turville SG, Santos JJ, Frank I, et al. Immunodeficiency virus uptake, turnover and 2-phase transfer in human dendritic cells. Blood 103, 2170–2176 (2004).
- Rowland-Jones SL. HIV: the deadly passenger in dendritic cells. Curr. Biol. 9, R248 (1999).
- Fan Z, Huang XL, Zheng L, et al Cultured blood dendritic cells retain HIV-1 antigen-presenting capacity for memory CTL during progressive HIV-1 infection. J. Immunol. 159, 4973 (1997).
- Chassin D, Andrieu M, Cohen W, et al. Dendritic cells transfected with the nef genes of HIV-1 primary isolates specifically activated cytotoxic T-lymphocytes from seropositive subjects. Eur. J. ImmonoL 29, 196 (1999).
- Rose BD (Ed.), Wellesley, MA, USA (2003).
- Soto-Ramirez LE, Renjifo B, McLane MF, et al. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science 271, 1291–1293 (1996).
- Pope M, Frankel SS, Mascola JR, et al. Human immunodeficiency virus Type 1 strains of subtypes B and E replicate in cutaneous dendritic cell—T-cell mixtures without displaying subtype-specific tropism. J. ViroL 71,8001-8007 (1997).
- Ditmar MT, Simmons G, Hibbitts S, et al. Langerhans cell tropism of human immunodeficiency virus Type 1 subtype A through F isolates derived from different transmission groups. J. ViroL 71, 8008–8013 (1997).
- Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV Type 1. J. Infect. Dis. 189, 286–291 (2004).
- Cole KJ, Nadler JP. Pathophysiology of HIV infection. In: HIV/AIDS Primary Care Guide. Florida AIDS Education and Training Center, University of Florida, FL, USA (2002).
- Harouse JM, Buckner C, Gettie A, et al. CD8 T-cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc. Natl Acad. Sci. USA 100, 10977–10982 (2003).
- Blaak H, van't Wout AB, Brouwer M, et al. In vivo HIV-1 infection of CD45RA± CD4 + T-cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4+ T-cell decline. Proc. Natl Acad. Sci. USA 97, 1269 (2000).
- Dewhurst S, Whetter L. Pathogenesis and treatment of HIV-1 infection: recent developments. Frontiers Biosci. 2 D147—D159 (1997).
- Luster AD. Mechanisms of disease: chemokines — chemotactic cytokines that mediate inflammation. N Engl. J. Med. 338, 436–445 (1998).
- •Excellent introduction to the role of chemoldnes; especially notable for illustrations and graphics.
- Bennett D, Aaidi I, Heneine W, et al. Prevalence of mutations associated with antiretroviral drug resistance among recently diagnosed persons with HIV, 1998–2000. Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (2002) (Abstract 372).
- Grant RI, Kahn JO, Warmerdam M, et al Transmission and transmissibility of drug-resistant HIV-1. Acute infection: resistance, fitness, and transmission. Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infictions (2002) (Abstract 368).
- Cheonis N. Tripranavir: the first nonpeptidic protease inhibitor. BETA 16, 15–17 (2000).
- De Felici A. Global HIV drug resistance surveillance. Scand J Infect. Dis. Suppl 35, 21–23 (2003).
- Lalezari JP, Henry K' Hearn M, O, et al Enfiwirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348, 2175–2185 (2003).
- Rhew DC, Bernal M, Aguilar D, Iloeje U, Goetz MB. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin. Infict. Dis. 37, 959–972 (2003).
- Rose BD (Ed.), Wellesley, MA, USA (2003).
- Kahn JO, Walker, BD. Acute human immunodeficiency virus Type 1 infection. N Engl J Med 339, 33 (1998).
- Lum JJ, Cohen OJ, Nie Z, et al Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis.j Clin. Invest. 111, 1547–1554 (2003).
- Strebel K. Virus—host interactions: role of HIV proteins Vif, Tat, and Rev. AIDS. 17(Suppl.), S25—S34 (2003).
- Otake K, Omoto S, Yamamoto T, et al HIV-1 Nef protein in the nucleus influences adipogenesis as well as viral transcription through the peroxisome proliferator-activated receptors. AIDS 18, 189–198 (2004).
- Ito Y, Grivel J, Chen S, Kiselyeva Y, Reichelderfer P, Margolis L. CXCR4-tropic HIV-1 suppresses replication of CCR5-tropic HIV-1 in human lymphoid tissue by selective induction of CC-chemokines. J. Infect. Dis. 189, 506–514 (2003).
- Cohen OJ, Fauci AS. Current strategies in the treatment of HIV infection. Dis. Mon. 48(3) 150 (2002).
- Fischer M, Joos B, Wong JK, et al. Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy. J. Infect. Dis. 189, 273–284 (2004).
- Pantaleo G, Perrin L. Can HIV be eradicated? AIDS 12(Suppl.), 175–180 (1998).
- Saag M. Is it time to proactively switch successful antiretroviral therapy? Carefully check you SWATCH. Ann. Intern. Med. 139, 148–149 (2003).
- Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J. Infect. Dis. 88, 1659–1665 (2003).
- •Sheds light on the uncertainty of when to begin antiretroviral therapy with a CD4 count between 200 and 350. This study is notable for having one of the longest follow-up periods of similar studies.
- Kaplan JE, Hanson DL, Cohn DL, et al. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4 + lymphocyte counts 350 cells/ul. Clin. Infect. Dis. 37, 951–958 (2003).
- •Clarifies when to begin antiretroviral therapy with a CD4 count between 200 and 350.
- Palella FJ, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4 + cell strata. Ann. Intern. Med. 138, 620–626 (2003).
- Panel on Clinical Practices for Treatment of HIV Infection. Convened by the Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (2003).
- Eron JJ, Feinber J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J. Infect. Dis. 189, 265–272 (2004).
- Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J. Med. 349, 2293–2303 (2003).
- Skolnik PR. HIV therapy — what do we know, and when do we know it? N Engl J. Med. 349, 2351-2352 (2003). Balzarini J. Inhibition of human 101 immunodeficiency virus by a new class of pyridine oxide derivatives. Anti micro b. Agents Chemother. 47, 2951–2957 (2003).
- Shafer RW, Smeaton LM, Robbins GK, et al Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 349, 2304–2315 (2003).
- Zaccarelli M, Pemo CF, Forbici F, et al Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy. Clin. Infect. Dis. 38,433–438 (2004).
- •Convincing report on a cohort of almost 500 patients who underwent genotype resistance testing after failure of therapy; supports the use of lamivudine.
- Olson WC, Maddon PJ. Resistance to HIV-1 entry inhibitors. Curr Drug Targets Infict Disord 3, 283–294 (2003).
- Jacobson JM, Israel RJ, Lowy I, et al Treatment of advanced human immunodeficiency virus Type 1 disease with the viral entry inhibitor PRO 542. Antimicrob. Agents Chemother. 48,423–429 (2004).
- Joshi PJ, Fisher TS, Prasad VR. Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Curr Drug Targets Infect. Disord 3,383–400 (2003).
- Lee NS, Dohjima T, Bauer G, et al Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nature Biotech. 20, 500–505 (2002).
- Harborth J, Elbasir SM, Vandenburgh K, et al Sequence, chemical and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid DrugDev. 13, 83–105 (2003).
- Saurya S, Lichtenstein A, Karpas A. Deletions in env gene of HIV-1 in AIDS patients treated with highly active antiretroviral therapy (HAART). J. Med. Viral. 71, 167–172 (2003).
- Biswas P, Jiang X, Pacchia AL, Dougherty JP, Peltz SW The human immunodeficiency virus Type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy. J. Viral. 78, 2082–2087 (2004).
- Stevens M, Pannecouque C, De Clercq E, Balzarini J. Inhibition of human immunodeficiency virus by a new class of pyridine oxide derivatives. Antimicrob. Agents Chemother. 47, 2951–2957 (2003).
- Li Q, Schacker T, Carlis J, et al. Functional genomic analysis of response of HIV-1-infected lymphatic tissue to antiretroviral therapy. J. Infect. Dis. 189, 572–582 (2004).
- Pilcher DC, Eron JJ, Galvin S, Gay C, Cohen MS. Acute HIV revisited: new opportunities for treatment and prevention. J. Clin. Invest. 113, 937–945 (2004).
- •Provides a convincing rationale for treating acute HIV, and broadening screening strategies using specimen pooling for early detection in low prevalence populations.
- Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-01 after early treatment of acute infection. Nature 28, 523–526 (2000).
- Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia. Science 278, 1447–1450 (1997).
- Powderly WG, Mayer KH. Centers for Disease Control and Prevention revised guidelines or human immunodeficiency virus (HIV) counseling, testing and referral: targeting HIV specialists. Clin. Infect. Dis. 37, 813–819 (2003).
Websites
- Infectious Diseases Online, Second Edition. Cohen J, Powderly MD (Eds), Elsevier, USA (2003). www.idreference.com (Accessed July 2004)
- Business Wire. Phase I/II HIV gene therapy trial initiated, Enzo Biochem tells annual meeting: company now focused on five therapeutic platforms; Enzo Life Sciences building new direct sales group. www.aegis.com/news/bw/2004/BW0401 03.html (Accessed July 2004)